Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence - Concepedia

Concepedia

Publication | Closed Access

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

451

Citations

31

References

2005

Year

Richard A. Larson, Eric L. Sievers, Edward A. Stadtmauer, Bob Löwenberg, Elihu H. Estey, Hervé Dombret, Matthias Theobald, D. Voliotis, John M. Bennett, Maria Richie,

Abstract

When it was administered to patients with CD33-positive AML in first recurrence, single-agent GO induced a 26% remission rate with a generally acceptable safety profile.

References

	Year	Citations

Page 1